
Alpha Tau reports 100% response in glioblastoma trial
Key points
- Alpha Tau Medical (NASDAQ:DRTS) reported objective tumor responses in all six evaluable patients in its REGAIN trial for recurrent glioblastoma, with five complete responses and one partial response.
- Alpha Tau shares rose 11.21% to $14.88 in overnight trading as of November 15, compared with the November 13 closing price of $13.38.
- The company is continuing enrollment toward 20 patients to assess the feasibility and safety of its Alpha DaRT cancer treatment.
Alpha Tau Medical (NASDAQ:DRTS) reported objective tumor responses in all six evaluable patients with recurrent glioblastoma in its REGAIN trial, while all eight treated patients remained alive as of November 11, 2026.
The interim results showed a median follow-up of 6.9 months among the six evaluable patients, with median overall survival not yet reached and follow-up ranging from 3.1 to 11.6 months.
Five patients achieved complete responses and one achieved a partial response, although the three most recently assessed responses require confirmation, while follow-up scans showed asymptomatic necrosis or suspected necrosis in four patients and two scans could not distinguish necrosis from progression.
All eight patients received their planned Alpha DaRT source placements without unanticipated serious adverse events, although one previously reported serious seizure with temporary Todd's paralysis resolved following steroid treatment.
The U.S. REGAIN trial is designed to enroll up to 20 patients with recurrent glioblastoma who are unsuitable for surgical removal and have previously received central nervous system radiation, with enrollment and follow-up continuing.
Frequently asked questions
More from United States
Ascentage Pharma adds lisaftoclax to China reimbursement list
HUTCHMED expands cancer drug coverage for 2027
Pony.ai launches bZ4X robotaxis, targets 1,000 across China
Evotec secures $2.9 million Gates grant
Oculis gains FDA clearance for Privosegtor MS trials
Cineverse revenue skyrockets 110% to $26 million
